Skip to content

Study · Non-randomized trial · n = 35 · 2026

7 results

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.

Charles J, Belbezier A, Mouret S, Dreno B, Dalle S, Lebbe C, Hainaut-Wierzbicka E, Stefan A, de Quatrebarbes J, Dereure O, Zehou O, Mansard S and 11 more

Show all authors

Dupuy A, Dutriaux C, Grange F, Gaudy-Marqueste C, Montaudié H, Arnault JP, Le Corre Y, Kervarrec T, Quesada JL, Samimi M, Leccia MT

Cancer medicine1 Oct 2026

PMID42791653 (opens in a new tab)PMCIDPMC13615304 (opens in a new tab)DOI10.1002/cam4.72295 (opens in a new tab)PepBankPUB-42791653
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In advanced MCC, lanreotide disease control at 3 months was 11.4% in the full cohort.

    In plain wordsIn advanced MCC, disease control after 3 months of lanreotide was 11.4% in the full cohort.

    Peptide
    Lanreotide
    Outcome
    Not applicableDisease control in full cohort
    Study

    n = 35

    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    Disease control rate at 3 months
    11.4%
    full cohort

    Source sentences

    Summary
    The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort.
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  2. 02HumanNon-randomized trialEfficacy outcome

    In advanced MCC, disease control at 3 months with lanreotide was 33.3% (4) among evaluable patients, all with stable disease.

    In plain wordsIn advanced MCC, 33.3% of evaluable patients had stable disease after 3 months of lanreotide.

    Peptide
    Lanreotide
    Outcome
    Not applicableDisease control among evaluable patients
    Study

    n = 12

    Analysis
    Primary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    Disease control rate at 3 months
    33.3%
    evaluable patients, all with stable disease
    Patients with disease control
    4 patients
    evaluable patients at 3 months

    Source sentences

    Summary
    The DCR at 3 months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort.
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  3. 03HumanNon-randomized trialEfficacy outcome

    In advanced MCC treated with lanreotide, median overall survival was 3.1 months (95% CI, 2-5.5).

    In plain wordsIn advanced MCC treated with lanreotide, median survival was 3.1 months.

    Peptide
    Lanreotide
    Outcome
    Not applicableOverall survival
    Study

    n = 35

    Analysis
    Secondary
    Outcome group
    Mortality · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    Median overall survival
    3.1 months
    Kaplan-Meier
    Median overall survival 95% CI
    2 to 5.5 months
    Kaplan-Meier

    Source sentences

    Summary
    Kaplan-Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2-5.5) and 3.5 months (95% CI, 2.3-5.5), respectively.
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  4. 04HumanNon-randomized trialEfficacy outcome

    In advanced MCC treated with lanreotide, median progression-free survival was 3.5 months (95% CI, 2.3-5.5).

    In plain wordsIn advanced MCC treated with lanreotide, median time without progression was 3.5 months.

    Peptide
    Lanreotide
    Outcome
    Not applicableProgression-free survival
    Study

    n = 35

    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    Median progression-free survival
    3.5 months
    Kaplan-Meier
    Median progression-free survival 95% CI
    2.3 to 5.5 months
    Kaplan-Meier

    Source sentences

    Summary
    Kaplan-Meier analysis revealed median OS and PFS of 3.1 months (95% CI, 2-5.5) and 3.5 months (95% CI, 2.3-5.5), respectively.
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  5. 05HumanNon-randomized trialEfficacy outcome

    In advanced MCC, lanreotide did not differ significantly from the expected 20% response rate in intention-to-treat analysis (p = 0.205).

    In plain wordsIn advanced MCC, lanreotide did not differ significantly from the expected 20% response rate in the full cohort.

    Peptide
    Lanreotide
    Outcome
    No significant changeDisease control versus expected rate, intention-to-treat
    Study

    n = 35

    Comparator
    expected 20% response rate
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    p value versus expected response rate
    0.205
    intention-to-treat
    Expected response rate
    20%
    benchmark

    Source sentences

    Summary
    Statistical analyses showed no significant difference from the expected 20% response rate (p = 0.205 for intention-to-treat; p = 0.939 for per-protocol).
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  6. 06HumanNon-randomized trialEfficacy outcome

    In advanced MCC, lanreotide did not differ significantly from the expected 20% response rate in per-protocol analysis (p = 0.939).

    In plain wordsIn advanced MCC, lanreotide did not differ significantly from the expected 20% response rate in per-protocol analysis.

    Peptide
    Lanreotide
    Outcome
    No significant changeDisease control versus expected rate, per-protocol
    Study

    n: not reported in source

    Comparator
    expected 20% response rate
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Measurements

    p value versus expected response rate
    0.939
    per-protocol
    Expected response rate
    20%
    benchmark

    Source sentences

    Summary
    Statistical analyses showed no significant difference from the expected 20% response rate (p = 0.205 for intention-to-treat; p = 0.939 for per-protocol).
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.
  7. 07HumanObservational studyOther

    In advanced MCC treated with lanreotide, tumor SSTR expression did not correlate with treatment response.

    In plain wordsIn advanced MCC treated with lanreotide, tumor receptor expression was not linked to treatment response.

    Peptide
    Lanreotide
    Outcome
    No significant changeSSTR expression and response
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 28 daysAs given in this study (human).

    Source sentences

    Summary
    SSTR tumor expression did not correlate with treatment response.
    2 context sentences
    Summary · context
    To test this hypothesis, we conducted a Phase II, non-randomized, open trial investigating lanreotide in MCC patients with advanced disease (ClinicalTrials.gov identifier: NCT02351128).
    Summary · context
    Patients with Stage IIIB-IV MCC received lanreotide monotherapy (120 mg every 28 days) at any line of systemic therapy, until disease progression or unacceptable toxicity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02351128

Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues

University Hospital, Grenoblen = 35Apr 2015 to 15 May 2017

Carcinoma, Merkel Cell

Trial pageClinicalTrials.govUpdated 18 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.